Topical Corticosteroids and Glucocorticoid-Induced Osteoporosis—Cumulative Dose and Duration Matter
- 1 March 2021
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 157 (3), 269-270
- https://doi.org/10.1001/jamadermatol.2020.4967
Abstract
Glucocorticoids are used by an estimated 0.5% to 1.0% of adults for management of a range of conditions, from allergies and inflammatory diseases to cancer.1 Glucocorticoid use increases with age: more than 3% of adults older than 50 years and 5.2% older than 80 years use glucocorticoids.2 Despite the availability of a growing number of medications to modulate immune function and/or inflammation, evidence from the Danish National Patient Registry suggests that the prevalence of glucocorticoid use has remained remarkably stable for 17 years (1999-2016).3 Thus, any noteworthy adverse effects associated with glucocorticoid use could have substantial consequences not only for the individual, but also for public health. Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.Keywords
This publication has 14 references indexed in Scilit:
- Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control studyArchives of Osteoporosis, 2018
- Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trialsOsteoporosis International, 2015
- Arthritis & RheumatismArthritis & Rheumatism, 2014
- Prevalence of oral glucocorticoid usage in the United States: A general population perspectiveArthritis Care & Research, 2012
- Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysisAnnals Of The Rheumatic Diseases, 2008
- Fracture risk with intermittent high‐dose oral glucocorticoid therapyArthritis & Rheumatism, 2007
- A Meta-Analysis of Prior Corticosteroid Use and Fracture RiskJournal of Bone and Mineral Research, 2004
- Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practiceAnnals Of The Rheumatic Diseases, 2002
- Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse eventsThe American Journal of Medicine, 1994
- Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid ArthritisAnnals of Internal Medicine, 1993